TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of post-partum influenza vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Arch Drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast animation deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of fruit and vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of food acceptance of exposed fruits and vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk difference for all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Risk difference for FFR-oriented target vessel revascularization by PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Brain responses to working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain responses to declarative memory encoding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain responses to insomnia-related stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional connectivity within default-mode and limbic networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-operative pathology results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic results of FNAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Right Ventricular to Left Ventricular Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of kidney transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression Free Survival (2nd Line+ Population)
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (3rd Line+ Population)
Endpoint domain: Mortality/survival
Primary endpoint: Change in task-based fMRI activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of Natural Killer cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Language learning success
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under the Concentration-time Curve of BI 695501 in Plasma (AUC0-1368)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 695501 in Plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Total Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient reach
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Patients Who Refused Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pro-inflammatory marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Retention of IUD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of subjects with serious device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Survival rate after cardiorespiratory arrest
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of adequate sample for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing a Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated Weekly Change on WHO-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NRS Pain Score AUC (NRS*hr) - 1st 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS Pain Score AUC (NRS*hr) - 1st 12 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of LUTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom bother of LUTS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of hospitalization or death at day 7
Endpoint domain: Mortality/survival
Primary endpoint: Difference in antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of gynecologic rare malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis of left outflow tract defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of hypoplastic left heart syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Control Over the Amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effect of Metformin on Corus CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the Concentration Time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Concentration Time Curve Extrapolated to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed maximal concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nephrotic Syndrome Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Endothelial cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreased Hemangioma Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Numbers of participants with metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numbers of participants with obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numbers of participants with diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of endothelial dysfunction biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who had a histological study of their brain metastases
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who had a neurosurgery of their brain metastases
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who had a radiotherapy of their brain metastases
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who had a chemotherapy of their brain metastases
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Eating disorder symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Technical success rate of free-hand insertion of an ultra-slim endoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasminogen Activator Inhibitor-1 (PAI-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Alpha-2 Antiplasmin level (A2P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombin Activatable Fibrinolysis Inhibitor (TAFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tissue plasminogen activator (tPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effectiveness of Web-based instructions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: combined renal end-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fugl-Meyer Assessment Scale for stroke upper limb recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motricity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay onset of sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adherence to Study Drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of pleural thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary function at completion of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood lipid levels of Docosahexaenoic Acid (DHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute Treatment-related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in GI Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Remission rate (ulcerative colitis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent of Patients Achieving PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Bactericidal/permeability-increasing proteins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Timed Up and Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients With Biopsy Proven Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of prophylaxis against IPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of prophylaxis against IPA
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change in coronary artery calcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Suitability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in skin thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Days Without Prosthesis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acute change of subjective well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute change of subjective relaxation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of acute symptoms of anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Serious Bacterial Infections (SBIs)
Endpoint domain: Adverse events/effects
Primary endpoint: device and procedural adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC from time zero to time of last quantifiable concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time zero extrapolated to infinite time [AUC(INF)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Scale (HAM-D) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Anxiety Scale (HAM-A) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction associated with venous cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Maximum dermal interstitial concentration of BCT194
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the curve interstitial concentrations of BCT194
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diagnostic accuracy of initial clinical diagnosis of concussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of clinical diagnosis of post-concussion symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Glycemic Control (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants achieving ACR 50 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative covert stroke
Endpoint domain: Mortality/survival
Primary endpoint: Postintubation Cortisol (Baseline Cortisol Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Baseline Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol Level 60 Minutes After Cortisol Stimulating Test (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to onset of ECG changes diagnostic of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oral Health-Related Quality of Life (OHRQoL) - OHIP-14A
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oral Health-Related Quality of Life (OHRQoL) - 7 domains
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent change from baseline in Worst Itch Numeric Rating Scale (WI-NRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in affective states
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Bone Resorption Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Bone Turnover Markers by Serum N-Telo Peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Bone Turnover Markers by TRACP5b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of casual sebum level (μg/cm 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the number of Ki67-and PPAR-gamma-positive sebaceous gland cells in facial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Bone status in offspring at the age of one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Infusion-related Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Complete evaluation of untreated lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Frequency of Voiding or Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Depth of damage inside and/or outside the venous wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Persistence with Prolia® at 12 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Persistence with Prolia® at 24 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anxiety as Measured by the Hamilton Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression as Measured by the Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Encounters with health professionals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of change in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cerebral blood flow in the perihematoma region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum voluntary contraction (MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of new formulation aspirin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of post-ERCP Pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Analog mood scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: POMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EPS sx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change on Panic Disorder Severity Scale (PDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in occupational status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in absence from work due to sickness
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-inf, Adj) of L-Praziquantel (L-PZQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Approval of prosocial motivation to bone marrow donation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Abdominal compartment syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in serum-level of timothy specific IgG4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ambulatory physiological and activity data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device wearability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frailty Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) from time 0 to time t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time 0 to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergen-induced late asthmatic response (AUC of FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in asthma severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving target hemoglobin of 11 g/dL or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Use of vasoactive drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Cobalamin (vitamin B12) in Breast Milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Pyridoxal (vitamin B6) in Breast Milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Riboflavin (vitamin B2) in Breast Milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Niacin (vitamin B3) in Breast Milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Thiamin (vitamin B1) in Breast Milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Circumferential Measurements Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Reported Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-Reported Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: cancer detection rate of MR-US fusion biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: clinically significant cancer detection rate of MR-US fusion biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cancer detection rate of STRUS-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: clinically significant cancer detection rate of STRUS-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cancer detection rate of combined method (fusion + STRUS-B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes